High time for low-dose prospective clini
β
Robert S. DiPaola; Henry J. Durivage; Barton A. Kamen
π
Article
π
2003
π
John Wiley and Sons
π
English
β 49 KB
The article by Glode et al. in this issue reports on the empiric success, as defined by a decreased prostate specific antigen level and lack of toxicity, of metronomically delivered lowβdose chemotherapy for patients with hormoneβrefractory prostate carcinoma. The data presented were collected as a